Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018-Reference-Cited by-同舟云学术

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Published:2023-04 Issue: Volume:183 Page:38-48
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bylicki Olivier^ORCID,Tomasini Pascale,Radj Gervais,Guisier Florian,Monnet Isabelle^ORCID,Ricordel Charles,Bigay-Game Laurence,Geier Margaux,Chouaid Christos,Daniel Catherine,Swalduz Aurelie,Toffart Anne-Claire,Doubre Helene,Peloni Jean-Michel,Moreau Diane,Subtil Fabien,Grellard Jean-Michel,Castera Marie,Clarisse Benedicte,Martins-Lavinas Pedro-Henrique,Decroisette Chantal,Greillier Laurent^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA,2019

5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study);Lung Cancer;2024-07

2. Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study;Clinical and Translational Oncology;2024-06-27

3. Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications;Expert Review of Clinical Immunology;2024-06-26

4. Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib;Frontiers in Oncology;2024-05-21

5. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04